Cargando…
Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer
SIMPLE SUMMARY: Interstitial lung disease (ILD) is a life-threatening toxicity caused by chemoradiotherapy and durvalumab; however, the risk factors for ILD during durvalumab treatment after chemoradiotherapy have not been established in non-small-cell lung cancer patients. We examined whether inter...
Autores principales: | Daido, Wakako, Masuda, Takeshi, Imano, Nobuki, Matsumoto, Naoko, Hamai, Kosuke, Iwamoto, Yasuo, Takayama, Yusuke, Ueno, Sayaka, Sumii, Masahiko, Shoda, Hiroyasu, Ishikawa, Nobuhisa, Yamasaki, Masahiro, Nishimura, Yoshifumi, Kawase, Shigeo, Shiota, Naoki, Awaya, Yoshikazu, Suzuki, Tomoko, Kitaguchi, Soichi, Fujitaka, Kazunori, Nagata, Yasushi, Hattori, Noboru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776853/ https://www.ncbi.nlm.nih.gov/pubmed/36551721 http://dx.doi.org/10.3390/cancers14246236 |
Ejemplares similares
-
A Rare Combination of Dermatomyositis, Interstitial Pneumonia, and Lung Cancer in a Patient Treated with Immunosuppressive Therapy and Chemotherapy
por: Daido, Wakako, et al.
Publicado: (2017) -
Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease
por: Kawase, Shigeo, et al.
Publicado: (2011) -
Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer
por: Masuda, Takeshi, et al.
Publicado: (2020) -
Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor–Induced Interstitial Lung Disease Among Patients With Nonlung Cancers
por: Shimoji, Kiyofumi, et al.
Publicado: (2020) -
COVID-19 and acute exacerbation of interstitial lung disease
por: Kondoh, Yasuhiro, et al.
Publicado: (2021)